Free Trial

Kymera Therapeutics (KYMR) SEC Filings & 10K Form

Kymera Therapeutics logo
$40.66 +1.52 (+3.88%)
(As of 12/20/2024 05:16 PM ET)

Recent Kymera Therapeutics SEC Filings

DateFilerForm TypeView
12/02/2024
6:50 PM
Esposito Pamela (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
12/02/2024
3:41 PM
Esposito Pamela (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
11/14/2024
8:30 AM
Avoro Capital Advisors LLC (Filed by)
Kymera Therapeutics (Subject)
Form SC 13G/A
11/08/2024
9:52 AM
Kymera Therapeutics (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G/A
10/31/2024
7:13 AM
Kymera Therapeutics (Filer)
Form S-3ASR
10/31/2024
6:40 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/31/2024
6:45 AM
Kymera Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
09/17/2024
5:20 PM
Esposito Pamela (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
09/17/2024
3:40 PM
Esposito Pamela (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/26/2024
5:31 PM
Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/26/2024
3:32 PM
Horobin Joanna (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/26/2024
3:25 PM
Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/22/2024
4:06 PM
BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
Kymera Therapeutics (Issuer)
LAMPERT MARK N (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2024
3:15 PM
BAKER BROS. ADVISORS LP (Filed by)
Kymera Therapeutics (Subject)
Form SC 13D/A
08/22/2024
3:03 PM
667, L.P. (Reporting)
Baker Bros. Advisors LLC (0001580575) (Reporting)
BAKER BROS. ADVISORS LP (Reporting)
Baker Brothers Life Sciences LP (Reporting)
BAKER FELIX (Reporting)
BAKER JULIAN (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
08/20/2024
4:24 PM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/20/2024
3:31 PM
Kymera Therapeutics (Filer)
Form 424B5
08/07/2024
6:10 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/07/2024
6:15 AM
Kymera Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
07/25/2024
5:12 PM
Horobin Joanna (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/23/2024
4:17 PM
Horobin Joanna (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/16/2024
5:00 PM
Gollob Jared (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/16/2024
3:28 PM
Gollob Jared (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/15/2024
3:31 PM
Gollob Jared (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/09/2024
4:15 PM
Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/09/2024
3:16 PM
Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
07/09/2024
3:18 PM
Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/28/2024
4:05 PM
BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
Kymera Therapeutics (Issuer)
LAMPERT MARK N (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/28/2024
7:30 AM
Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:00 PM
Kymera Therapeutics (Issuer)
Morgan Leigh (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:00 PM
Kymera Therapeutics (Issuer)
MARAGANORE JOHN (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:00 PM
Hrustanovic Gorjan (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:00 PM
Kymera Therapeutics (Issuer)
Ridloff Elena (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:00 PM
Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:00 PM
Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:00 PM
Esposito Pamela (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/20/2024
4:01 PM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/20/2024
7:30 AM
Kymera Therapeutics (Issuer)
Mainolfi Nello (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/14/2024
5:01 PM
Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/13/2024
4:14 PM
Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/13/2024
4:15 PM
Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Vladimir Lenin was right… (Ad)

The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.
06/12/2024
4:23 PM
Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/12/2024
4:24 PM
Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
06/07/2024
5:36 PM
Horobin Joanna (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/07/2024
3:27 PM
Horobin Joanna (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/23/2024
4:22 PM
Chadwick Jeremy G (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/02/2024
6:10 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/02/2024
6:10 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/02/2024
6:15 AM
Kymera Therapeutics (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/24/2024
3:15 PM
Kymera Therapeutics (Filer)
Form ARS
04/24/2024
3:06 PM
Kymera Therapeutics (Filer)
Form DEF 14A
04/24/2024
3:10 PM
Kymera Therapeutics (Filer)
Form DEFA14A
04/01/2024
7:53 AM
BAKER BROS. ADVISORS LP (Reporting)
Kymera Therapeutics (Issuer)
Form 3
Initial statement of beneficial ownership of securities  
04/01/2024
7:56 AM
667, L.P. (Reporting)
Baker Bros. Advisors LLC (0001580575) (Reporting)
BAKER BROS. ADVISORS LP (Reporting)
Baker Brothers Life Sciences LP (Reporting)
BAKER FELIX (Reporting)
BAKER JULIAN (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
04/01/2024
7:57 AM
BAKER BROS. ADVISORS LP (Filed by)
Kymera Therapeutics (Subject)
Form SC 13D
04/01/2024
6:00 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/15/2024
6:23 PM
Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/15/2024
3:30 PM
Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/14/2024
4:01 PM
Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/14/2024
4:02 PM
Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/13/2024
6:52 PM
Booth Bruce (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2024
6:53 PM
Atlas Venture Associates Opportunity I, L.P. (Reporting)
Atlas Venture Associates Opportunity I, LLC (Reporting)
ATLAS VENTURE ASSOCIATES X, L.P. (Reporting)
Atlas Venture Associates X, LLC (Reporting)
Atlas Venture Fund X, L.P. (Reporting)
Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/13/2024
3:55 PM
Atlas Venture Opportunity Fund I, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/13/2024
3:55 PM
Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/12/2024
4:17 PM
Atlas Venture Fund X, L.P. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2024
5:21 PM
Gollob Jared (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
03/04/2024
4:47 PM
Jacobs Bruce N. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
03/04/2024
4:50 PM
Gollob Jared (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/29/2024
3:34 PM
Gollob Jared (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/27/2024
3:22 PM
Gollob Jared (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/22/2024
6:32 AM
Kymera Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/22/2024
6:10 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/22/2024
6:16 AM
Kymera Therapeutics (Filer)
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/21/2024
5:46 PM
Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/14/2024
8:15 AM
Avoro Capital Advisors LLC (Filed by)
Kymera Therapeutics (Subject)
Form SC 13G/A
02/12/2024
9:03 AM
Kymera Therapeutics (Subject)
PRICE T ROWE ASSOCIATES INC /MD/ (Filed by)
Form SC 13G/A
02/12/2024
9:07 AM
Kymera Therapeutics (Subject)
PRICE T ROWE ASSOCIATES INC /MD/ (Filed by)
Form SC 13G/A
02/09/2024
6:47 PM
Gollob Jared (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
02/08/2024
9:21 AM
Kymera Therapeutics (Subject)
WELLINGTON MANAGEMENT GROUP LLP (Filed by)
Form SC 13G/A
01/29/2024
2:26 PM
BlackRock Inc. (Filed by)
Kymera Therapeutics (Subject)
Form SC 13G/A
01/23/2024
6:37 PM
Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/23/2024
3:19 PM
Albers Jeffrey W. (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
01/23/2024
9:31 AM
Kymera Therapeutics (Subject)
STATE STREET CORP (Filed by)
Form SC 13G/A
01/10/2024
3:52 PM
BAKER BROS. ADVISORS LP (Filed by)
Kymera Therapeutics (Subject)
Form SC 13G/A
01/09/2024
3:45 PM
BIOTECHNOLOGY VALUE FUND L P (Filed by)
Kymera Therapeutics (Subject)
Form SC 13D/A
01/09/2024
3:49 PM
BIOTECHNOLOGY VALUE FUND II LP (Reporting)
BIOTECHNOLOGY VALUE FUND L P (Reporting)
Biotechnology Value Trading Fund OS LP (Reporting)
BVF GP HOLDINGS LLC (Reporting)
BVF I GP LLC (Reporting)
BVF II GP LLC (Reporting)
BVF INC/IL (Reporting)
BVF PARTNERS L P/IL (Reporting)
BVF Partners OS Ltd. (Reporting)
Kymera Therapeutics (Issuer)
LAMPERT MARK N (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2024
4:15 PM
Chiniara Ellen (Reporting)
Kymera Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
01/05/2024
3:11 PM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/04/2024
3:01 PM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/04/2024
3:06 PM
Kymera Therapeutics (Filer)
Form 424B5
01/04/2024
8:29 AM
Chiniara Ellen (Reporting)
Kymera Therapeutics (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
Why Buffett, Griffin and 100 members of Congress are Piling into this One Investment (Ad)

This isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.

01/04/2024
6:08 AM
Kymera Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/02/2024
4:43 PM
Kymera Therapeutics (Issuer)
Mainolfi Nello (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:KYMR) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners